Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1987-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/PNAS.84.22.8160PMID 2891137PMCID PMC299498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP).

  1986cited by this paper
• A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of 3H2O and adsorption of [3H]-tyrosine by charcoal.

  1986cited by this paper
• Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.

  1986cited by this paper
• 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice.

  1986cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes.

  1986cited by this paper
• Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.

  1986cited by this paper
• MPTP, a neurotoxin producing a Parkinsonian syndrome

  1986cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP.

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.

  1985cited by this paper
• Measurement of protein using bicinchoninic acid.

  1985cited by this paper
• Pargyline prevents MPTP-induced parkinsonism in primates.

  1984cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• Aetiology of Parkinson's disease.

  1983cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Catecholamine secretion from digitonin-treated adrenal medullary chromaffin cells.

  1983cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• Characterization of ascorbic acid transport by adrenomedullary chromaffin cells. Evidence for Na+-dependent co-transport.

  1983cited by this paper
• Osmotic pressures of solutions of ATP and catecholamines relating to storage in chromaffin granules.

  1982cited by this paper
• Reserpine increases opiate-like peptide content and tyrosine hydroxylase activity in adrenal medullary chromaffin cells in culture.

  1981cited by this paper
• Primary culture of adrenal medullary chromaffin cells in a chemically defined medium.

  1981cited by this paper
• The character of the stored molecules in chromaffin granules of the adrenal medulla: a nuclear magnetic resonance study.

  1978cited by this paper
• Catecholamine uptake processes.

  1973cited by this paper

• Exploring α-Syn’s Functions Through Ablation Models: Physiological and Pathological Implications

  2025cites this paper
• How do batrachotoxin-bearing frogs and birds avoid self intoxication?

  2021cites this paper
• Revisiting the Paraquat-Induced Sporadic Parkinson’s Disease-Like Model

  2018cites this paper
• Clathrin-Dependent Uptake of Paraquat into SH-SY5Y Cells and Its Internalization into Different Subcellular Compartments

  2017cites this paper
• Current Status, Gaps, and Weaknesses of the Mechanism of Selective Dopaminergic Toxicity of MPTP/MPP+

  2017cites this paper
• FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.

  2016cites this paper
• Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+

  2015cites this paper
• A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections.

  2015cites this paper
• Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons.

  2014cites this paper
• Biochemical evaluation of the neurotoxicity of MPTP and MPP⁺ in embryonic and newborn mice.

  2013cites this paper
• Changes of MAO-A and MAO-B Expressions in the Placenta of MPTP or MPP+ Treated Mice

  2013cites this paper
• Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

  2013cites this paper
• Involvement of monoamine oxidase-B in the acute neurotoxicity of MPTP in embryonic and newborn mice.

  2013cites this paper
• Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.

  2012cites this paper
• Nomifensine alters sex differences in striatal dopaminergic function

  2012cites this paper
• The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.

  2012cites this paper
• Markers associated with testosterone enhancement of methamphetamine-induced striatal dopaminergic neurotoxicity.

  2012cites this paper
• Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry

  2011cites this paper
• Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.

  2010influential citation
• GSH-DA interactions: relevance to cell vulnerability in Parkinson's disease

  2010cites this paper
• Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

  2009cites this paper
• Catecholamine disturbance and SH-SY5Y cell toxicity of halogenated 3-amino-2 phenylpropenes

  2009cites this paper
• Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function.

  2008cites this paper
• Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP

  2008cites this paper
• Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish.

  2008cites this paper
• Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

  2008cites this paper
• Sex Differences in K+‐Evoked Striatal Dopamine Output from Superfused Striatal Tissue Fragments of Reserpine‐Treated CD‐1 Mice

  2007cites this paper
• Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult.

  2007cites this paper
• Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells

  2007cites this paper
• Modeling Neurodegenerative Diseases in vivo Review

  2006cites this paper
• Testosterone modulation of striatal dopamine output in orchidectomized mice

  2006cites this paper
• The release of 3H-1-methyl-4-phenylpyridinium from bovine adrenal chromaffin cells is modulated by somatostatin.

  2006cites this paper
• Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells.

  2005cites this paper
• Dopamine transporter function differences between male and female CD-1 mice.

  2005cites this paper
• Multi-level regulation of Thy-1 antigen expression in mouse T lymphomas

  2004cites this paper
• Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP

  2004cites this paper
• The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).

  2004cites this paper
• Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter‐2: Human midbrain dopamine neurons

  2004cites this paper
• Genes, proteins, and neurotoxins involved in Parkinson's disease.

  2004cites this paper
• INTERACTION OF VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) AND NEUROMELANIN PIGMENT AMONG THE MIDBRAIN DOPAMINERGIC NEURONS, IN MAN

  2004cites this paper
• Antisense Evidence for Nuclear Factor-κB–Dependent Embryopathies Initiated by Phenytoin-Enhanced Oxidative Stress

  2004cites this paper
• Parkinson's Disease Mechanisms and Models

  2003cites this paper
• Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits

  2003cites this paper
• Environmental factors in Parkinson's disease.

  2002cites this paper
• A Role for the Vesicular Monoamine Transporter (VMAT2) in Parkinson’s Disease

  2002cites this paper
• Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.

  2002cites this paper
• 2 (cid:1) -NH 2 -MPTP [1-Methyl-4-(2 (cid:1) -aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2 (cid:1) -CH 3 -MPTP [1-Methyl-4-(2 (cid:1) -methylphenyl)-1,2,3,6-tetrahydropyridine]

  2002cites this paper
• 2′-NH2-MPTP [1-Methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2′-CH3-MPTP [1-Methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine]

  2002cites this paper
• 2 (cid:1) -NH 2 -MPTP [1-Methyl-4-(2 (cid:1) -aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2 (cid:1) -CH 3 -MPTP [1-Methyl-4-(2 (cid:1) -methylphenyl)-1,2,3,6-tetrahydropyridine]

  2002cites this paper
• Comparison of the effect of cyclic AMP on the content and release of dopamine and 1-methyl-4-phenylpyridinium (Mpp+) in PC12 cells.

  2002cites this paper
• MPTP: insights into parkinsonian neurodegeneration.

  2002cites this paper
• Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP

  2002cites this paper
• Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  2001cites this paper
• Norsalsolinol uptake into secretory vesicles via vesicular monoamine transporter and its secretion by membrane depolarization or purinoceptor stimulation in PC12 cells.

  2001cites this paper
• Protective Effects of Riluzole on Dopamine Neurons

  2000cites this paper
• Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity

  2000cites this paper
• Involvement of Dopamine Transporters in Psychiatric Disorders

  2000cites this paper
• Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.

  2000cites this paper
• Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.

  2000cites this paper
• In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.

  2000cites this paper
• The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation

  2000cites this paper
• Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.

  1999cites this paper
• MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1).

  1999cites this paper
• Selective neurotoxins, chemical tools to probe the mind: The first Thirty years and beyond

  1999cites this paper
• Dopamine transporters and neuronal injury.

  1999cites this paper
• The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.

  1998cites this paper
• Ligand recognition by the vesicular monoamine transporters.

  1998cites this paper
• The vesiicular monoamine transporter: from chromaffin granule to brain

  1998cites this paper
• MPTP-Induced Modulation of Neurotransmitters in SH-SY5Y Human Neuroblastoma Cells

  1998cites this paper
• Role of Heat Shock Proteins in MPTP‐Induced Neurotoxicity

  1997cites this paper
• (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.

  1997cites this paper
• The Role of Glutathione in the Pathogenesis of Parkinson’s Disease

  1997cites this paper
• MPTP: A Dopaminergic Neurotoxin

  1997cites this paper
• Phosphorylation of a Vesicular Monoamine Transporter by Casein Kinase II*

  1997cites this paper
• Highly Selective Neurotoxins

  1997influential citation
• ( (cid:49) )MK-801 Does Not Prevent MPTP-Induced Loss of Nigral Neurons in Mice 1

  1997cites this paper
• The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent.

  1996cites this paper
• Heat shock proteins protect cultured fibroblasts from the cytotoxic effects of MPP+.

  1996cites this paper
• Drug interactions with vesicular amine transport.

  1996cites this paper
• Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.

  1996cites this paper
• Heterogeneity of monoaminergic vesicular carriers: pharmacological evidence using MPP+ as a marker.

  1996cites this paper
• Age‐Dependent Sensitivity of Cultured Peripheral Sympathetic Neurons to 1‐Methyl‐4‐Phenylpyridinium: Role of Glutathione

  1996cites this paper
• Dopaminergic systems and parkinson's disease: Some latest developments in pathogenetic, diagnostic and pharmacotherapeutic investigations

  1996cites this paper
• Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

  1996cites this paper
• Chapter 26 The transport of neurotransmitters into synaptic vesicles

  1995cites this paper
• A molecular analysis of vesicular amine transport.

  1995cites this paper
• The transport of neurotransmitters into synaptic vesicles.

  1995cites this paper
• Differences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1994cites this paper
• What is it that l‐deprenyl (selegiline) might do? *

  1994cites this paper
• In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.

  1994cites this paper
• The molecular cloning and expression of a human synaptic vesicle amine transporter that suppresses MPP+ toxicity.

  1994cites this paper
• Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats

  1994cites this paper
• A Molecular Glimpse of Vesicular Monoamine Transporters

  1994cites this paper
• Use of an electrode selective for 1-methyl-4-phenylpyridinium (MPP+) to measure its uptake and accumulation by mitochondria.

  1993cites this paper
• Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: a proton gradient drives its uptake through monoamine transporter.

  1993cites this paper
• Neural degeneration and the transport of neurotransmitters

  1993cites this paper
• Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds

  1993cites this paper
• Adrenomedullary Chromaffin Cells for Toxicological Studies

  1993cites this paper
• MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.

  1993cites this paper
• 1‐Methyl‐4‐(2′‐Ethylphenyl)‐1,2,3,6‐Tetrahydropyridine‐ Induced Toxicity in PC12 Cells Is Enhanced by Preventing Glycolysis

  1992cites this paper